Research programme: CNS disorder therapeutics - Aprecia PharmaceuticalsAlternative Names: Oxcarbazepine - Aprecia Pharmaceuticals; Product 2 - Aprecia Pharmaceuticals; Product 3 - Aprecia Pharmaceuticals; Product 4 - Aprecia Pharmaceuticals
Latest Information Update: 16 Jul 2015
Price : *
At a glance
- Originator Aprecia Pharmaceuticals
- Class Dibenzazepines; Pyrrolidinones; Small molecules
- Mechanism of Action Sodium channel antagonists; SV2A protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical CNS disorders
Most Recent Events
- 16 Jul 2015 Aprecia has patent protection for oxcarbazepine and levetiracetam
- 16 Jul 2015 Aprecia Pharmaceuticals plans regulatory submissions for CNS disorders (Aprecia Pharmaceuticals pipeline, July 2015)
- 15 Jul 2015 Aprecia has patent protection for Zipdose® (Aprecia website, July 2015).